-
Bifendate (DDB): Mechanisms and Research Use
2026-09-29
Bifendate, also called DDB, is a synthetic Schisandrin C derivative studied as a hepatoprotection agent and autophagy inhibitor. Product documentation describes effects on hepatic lipid accumulation, lysosomal autophagy, CYP3A4, P-glycoprotein, and inflammation-related targets, while available evidence remains model- and condition-dependent.
-
MMP7 Drives EMT in Biliary Atresia Fibrosis
2026-09-29
A 2026 study identifies MMP7 as a mechanistic link between biliary epithelial injury, E-cadherin cleavage, β-catenin nuclear translocation, and progressive liver fibrosis in biliary atresia. Its integrated clinical, bioinformatic, cellular, and mouse-model evidence supports MMP7 blockade as an antifibrotic strategy and clarifies how downstream β-catenin signaling could be investigated.
-
FBXO22 Recruitment Ligands and 2-PCA Degraders
2026-09-28
This 2025 bioRxiv preprint introduces chemical probes that either remove FBXO22 itself or use FBXO22 as a recruitment component in targeted protein degradation. Its central advance is the identification of 2-pyridinecarboxaldehyde as a reversible electrophilic degron that supports FBXO22-dependent degradation of BRD4 and CDK12.
-
CFTRinh-172: Functional Assays and Workflow Guide
2026-09-28
Use CFTRinh-172 to isolate acute CFTR channel activity from changes in cAMP signaling or channel trafficking. This workflow pairs functional blockade with surface-protein assays, helping researchers interpret results across epithelial models without mistaking channel inhibition for a trafficking effect.
-
Hepatic sEH Links Redox Signaling to Osteoporosis
2026-09-27
This study identifies a liver-to-bone mechanism in which hepatic soluble epoxide hydrolase (sEH) is associated with altered circulating epoxide metabolites and inflammatory signals, reduced Nrf2-ARE activity, and enhanced osteoclast differentiation. Evidence from patient samples, ovariectomy-induced osteoporosis mice, and cell experiments supports the proposed pathway, while leaving important questions about clinical causality and therapeutic translation open.
-
TXA–NO–Propolis Dressings for Rapid Hemostasis
2026-09-26
A 2024 study reports a bilayer wound dressing that combines tranexamic acid (TXA), propolis, and the nitric oxide donor SNAP to support rapid clot stabilization alongside antibacterial activity. The findings highlight a promising materials-based approach to traumatic wound care, while remaining preclinical and unable to isolate the contribution of each component.
-
CGRP/SP–Piezo2 Signaling in Trigeminal Allodynia
2026-09-25
Liao et al. connect trigeminal root compression and neuroinflammation to mechanical allodynia through a Ca²⁺-dependent CGRP/SP–Piezo2 feedback loop. Their rat and cell-based experiments point to peripheral neuron–Merkel cell signaling as a candidate mechanism, while leaving important questions about human relevance and pathway specificity open.
-
Polybrene Workflows for Gene Delivery and Metabolism
2026-09-25
Polybrene can improve viral delivery and lipid-mediated transfection, helping researchers build perturbation models for questions such as how TCAIM regulates OGDH. This practical guide separates delivery-reagent effects from metabolic biology and provides a dose-finding workflow, controls, and troubleshooting guidance.
-
From Plasmin Biology to Clot-Stabilizing Materials
2026-09-24
Tranexamic Acid lets translational researchers examine clot persistence separately from clot formation. This article connects its plasmin-directed mechanism to a 2024 wound-dressing study, then outlines experimental design choices, interpretation limits, and the next steps needed to move from biochemical assays toward material-level validation.
-
Merimepodib (VX-497) in PEDV Research
2026-09-24
Use Merimepodib (VX-497) to test whether IMPDH-dependent guanine nucleotide synthesis supports PEDV replication, pairing pharmacological inhibition with genetic and metabolic readouts. This guide separates findings reported in the study from practical starting conditions for dose-finding, specificity checks, and troubleshooting.
-
Immobilized Microalgae for Antioxidant Active Packaging
2026-09-23
This study combines silk fibroin–reinforced alginate immobilization with microalgal extract incorporation into biodegradable films. Immobilization increased biomass and polysaccharide production, while the resulting extract improved film antioxidant and moisture-barrier performance and helped preserve apple slices.
-
Tranexamic Acid Workflows for Clot Stability
2026-09-23
Translate Tranexamic Acid mechanism into reproducible plasmin, clot-stability, and biomaterial assays. This guide connects concentration-controlled fibrinolysis research with the instant clot-forming dressing strategy reported in a 2024 reference study.
-
CFTRinh-172: Selective CFTR Inhibitor Guide
2026-09-22
CFTRinh-172 is a reversible, voltage-independent CFTR inhibitor for functional studies of epithelial chloride transport. Product data support its use in cystic fibrosis research and preclinical secretory diarrhea models, but not as a clinical treatment.
-
ERAD Hijacking for Transmembrane Protein Degradation
2026-09-22
Song et al. establish ERAD-engaging chimeras (ERADECs), a small-molecule targeted protein degradation platform that redirects endoplasmic reticulum quality control toward transmembrane proteins. By using desonide to recruit the ER E3 ligase SYVN1, the study achieves potent PD-L1 degradation, tumor suppression, and initial extension to mutant HTT protein.
-
ALDOB K87 Lactylation in Pulmonary Hypertension
2026-09-21
The reference study identifies ALDOB K87 lactylation as a mechanistic link between hypoxia-driven glycolysis, mitochondrial fission, and pulmonary artery smooth muscle cell remodeling. Its lactate–ALDOB–DRP1 model provides a framework for studying how metabolic post-translational modifications may sustain pulmonary hypertension, while also highlighting experimental limitations that matter for translation.